---
companies:
- category: unknown
  confidence: medium
  context: Welcome everyone to the AI and Business Podcast. I'm Matthew Damello, Editorial
    Director here at
  name: Business Podcast
  position: 31
- category: unknown
  confidence: medium
  context: come everyone to the AI and Business Podcast. I'm Matthew Damello, Editorial
    Director here at Emerge AI Research. T
  name: Matthew Damello
  position: 53
- category: unknown
  confidence: medium
  context: the AI and Business Podcast. I'm Matthew Damello, Editorial Director here
    at Emerge AI Research. Today's guest is Patr
  name: Editorial Director
  position: 70
- category: unknown
  confidence: medium
  context: . I'm Matthew Damello, Editorial Director here at Emerge AI Research. Today's
    guest is Patricio Lurosa, Head of N2N De
  name: Emerge AI Research
  position: 97
- category: unknown
  confidence: medium
  context: ctor here at Emerge AI Research. Today's guest is Patricio Lurosa, Head
    of N2N Decision Science in Seed Production
  name: Patricio Lurosa
  position: 134
- category: unknown
  confidence: medium
  context: ch. Today's guest is Patricio Lurosa, Head of N2N Decision Science in Seed
    Production Innovation at Bayer Crop Scien
  name: Decision Science
  position: 163
- category: unknown
  confidence: medium
  context: Patricio Lurosa, Head of N2N Decision Science in Seed Production Innovation
    at Bayer Crop Science. He joins us today to explo
  name: Seed Production Innovation
  position: 183
- category: unknown
  confidence: medium
  context: Decision Science in Seed Production Innovation at Bayer Crop Science. He
    joins us today to explore how artificial inte
  name: Bayer Crop Science
  position: 213
- category: unknown
  confidence: medium
  context: ecutive thought leaders, everyone from the CIO of Goldman Sachs, to the
    head of AI at Raytheon and AI pioneers li
  name: Goldman Sachs
  position: 944
- category: unknown
  confidence: medium
  context: o the head of AI at Raytheon and AI pioneers like Yoshua Benjiro. With
    nearly a million annual listeners, AI and B
  name: Yoshua Benjiro
  position: 1010
- category: unknown
  confidence: medium
  context: eve you can help other leaders move the needle on AI ROI, visit emerj.com
    and fill out our thought leader
  name: AI ROI
  position: 1480
- category: unknown
  confidence: medium
  context: or the clinical practice right there in the data? What I mean to say is
    that when you are in the space of
  name: What I
  position: 6601
- category: unknown
  confidence: medium
  context: at we can use it in the clinical practice. Right. So I am going to, I develop
    an FMRI, a magnetic resona
  name: So I
  position: 7730
- category: unknown
  confidence: medium
  context: ve the test to prove whether the drug is working. So AI today is opening
    this opportunity for us to analy
  name: So AI
  position: 8434
- category: unknown
  confidence: medium
  context: ign, whereas huge computational need. Guess what? When I go to the clinical
    practice, those models are goi
  name: When I
  position: 8937
- category: unknown
  confidence: medium
  context: comes to trust and building trust with patients. But I think this was an
    important answer to hear. And I
  name: But I
  position: 9935
- category: unknown
  confidence: medium
  context: But I think this was an important answer to hear. And I want to draw a
    couple questions under it for the
  name: And I
  position: 9985
- category: unknown
  confidence: medium
  context: . For others, it is actually until the rebirth of Neural Networks back
    in 2010 when they came back alive, upon afte
  name: Neural Networks
  position: 14916
- category: unknown
  confidence: medium
  context: ain social media experiences after generative AI. If I'm blurred my background
    right now, you know, you'
  name: If I
  position: 16222
- category: unknown
  confidence: medium
  context: two eyes, which might need to be another podcast. Now I think I understand
    the more the question and I wi
  name: Now I
  position: 17095
- category: ai_media_analysis
  confidence: high
  context: The organization hosting the 'AI and Business Podcast' and featuring executive
    thought leaders on AI adoption.
  name: Emerge AI Research
  source: llm_enhanced
- category: big_tech_finance_ai_user
  confidence: medium
  context: Mentioned as having a CIO who is an executive thought leader featured on
    the podcast, implying involvement in enterprise AI strategy.
  name: Goldman Sachs
  source: llm_enhanced
- category: big_tech_defense_ai_user
  confidence: medium
  context: Mentioned as having a head of AI who is an executive thought leader featured
    on the podcast, implying involvement in enterprise AI strategy.
  name: Raytheon
  source: llm_enhanced
- category: ai_research_figure
  confidence: high
  context: Referenced as an AI pioneer, likely referring to Yoshua Bengio, a prominent
    figure in deep learning research.
  name: Yoshua Benjiro
  source: llm_enhanced
- category: ai_research_institution
  confidence: medium
  context: Mentioned in the context of academic expertise where sensing technology
    needs to be good for both R&D and clinical practice.
  name: University of Laudis
  source: llm_enhanced
- category: ai_application_tool
  confidence: medium
  context: Mentioned as a product (developed by OpenAI, though OpenAI is not explicitly
    named) that people are using to self-educate on AI.
  name: ChatGPT
  source: llm_enhanced
- category: ai_research_setting
  confidence: high
  context: Mentioned as a place where people are not technically repairing too much
    regarding AI/ML differentiation.
  name: university
  source: llm_enhanced
- category: general_sector
  confidence: high
  context: Mentioned generally alongside the university regarding technical repair/differentiation.
  name: industry
  source: llm_enhanced
- category: technology_domain
  confidence: high
  context: Discussed as a critical, advancing field that must keep pace with AI advancements
    and potential misuse.
  name: cybersecurity
  source: llm_enhanced
date: 2025-08-05 06:00:00 +0000
duration: 29
has_transcript: false
layout: episode
llm_enhanced: true
original_url: https://traffic.libsyn.com/secure/techemergence/Business_-_8.5.25_-_Patricio_LaRosa.mp3?dest-id=151434
processing_date: 2025-10-04 19:34:59 +0000
quotes:
- length: 152
  relevance_score: 4
  text: But first, are you driving AI transformation at your organization, or maybe
    you're guiding critical decisions on AI investments, strategy, or deployment
  topics:
  - investment
- length: 150
  relevance_score: 4
  text: Second, the new opportunity in the market is that if you think about it, if
    I am owner of information, everyone would like to have a piece of the cake
  topics:
  - market
  - opportunity
- length: 135
  relevance_score: 3
  text: He joins us today to explore how artificial intelligence is reshaping clinical
    workflows from biomarker detection to patient engagement
  topics: []
- length: 146
  relevance_score: 3
  text: And a big part of why I love hosting the show, but you have to take a second
    and draw the different kinds of AI you're going to draw in each place
  topics: []
- length: 102
  relevance_score: 3
  text: What did you say that makes total sense that it's almost the answer to the
    problem is bring another AI
  topics: []
- length: 111
  relevance_score: 3
  text: Well, let me pause you right there because you have to deal with buy-in at
    two different levels above and below
  topics: []
- length: 150
  relevance_score: 3
  text: Also pitching this high and low, you have to keep the patient informed, but
    also you need to get that buy-in from management for these different forms
  topics: []
- length: 116
  relevance_score: 3
  text: Now, but if we are fair with the literature, the concept of artificial intelligence
    goes back to the 1970s and 1960s
  topics: []
- length: 123
  relevance_score: 3
  text: So I will say for some, everything that has been developed since then, big
    loans to the umbrella of artificial intelligence
  topics: []
- impact_reason: Articulates the 'R&D to Practice' scalability requirement for new
    technologies. Adoption and volume drive down the cost curve (economy of scale).
  relevance_score: 10
  source: llm_enhanced
  text: '...having a sensing technology needs to be good for R&D, but also needs to
    be good for the clinical practice. And once it is good, and you have many patients
    undergoing this, of course, the economy of the skills will lower the cost of this
    sensimulality.'
  topic: strategy/scalability
- impact_reason: 'Defines the challenge of ''industrializing'' R&D sensing technology:
    it must transition from a research tool to a cost-effective, scalable tool usable
    in routine clinical practice.'
  relevance_score: 10
  source: llm_enhanced
  text: What I mean to say is that when you are in the space of developing, right,
    or developing a clinical trial, you are measuring the effect using a sensing technology.
    Right. Okay. Hopefully that sensing technology is killed after the clinical trial
    finishes, and you can use in mental practice to detect the effect.
  topic: technical/scalability
- impact_reason: 'The core tension in HealthTech AI: advanced analytical capability
    (beautiful manners) is useless if the resulting technology isn''t economically
    scalable for widespread clinical use.'
  relevance_score: 10
  source: llm_enhanced
  text: AI today is opening this opportunity for us to analyze more data in beautiful
    manners compared than before. However, if they lead us to technology that is scalable
    to enable proper clinical practice and economical within economical constraints
    or reasonable economical constraints, that's a challenge.
  topic: limitations/business
- impact_reason: A stark assessment that current AI adoption has not yet impacted
    the fundamental, massive cost and time metrics of drug development, suggesting
    AI's impact is currently focused on specific process steps rather than the overall
    timeline.
  relevance_score: 10
  source: llm_enhanced
  text: even with all the AI that we've been seeing, even since the pandemic, no one
    or no gigantic body of research has been able to move the needle on one and a
    half to two something billion in costs and 10 to 15 years bringing it to market.
  topic: predictions/limitations
- impact_reason: Identifies regulatory inertia as the primary bottleneck preventing
    AI-driven scientific acceleration from translating into faster time-to-market.
  relevance_score: 10
  source: llm_enhanced
  text: The speed to identify markers has increased because you're able to analyze
    information in ways that you couldn't do before... However, if that means that
    we're able to accelerate the discoveries of markers that are more robust and reliable,
    the regulatory process has not changed. And so we might be faster today or feel
    that we are faster, but also that needs to go along the lines of understanding
    what are we going to do with the regulatory system in our intention to ensure
    that we can increase that speed. Otherwise, that will become the bottleneck.
  topic: safety/regulation
- impact_reason: Highlights Generative AI as a disruptive force that complicates established
    conceptual frameworks (deterministic vs. probabilistic) used to understand AI
    systems.
  relevance_score: 10
  source: llm_enhanced
  text: '...we''ve held this audience''s hand trying to get them to differentiate
    between deterministic and probabilistic technologies. Now we have GenAI coming
    down the pike, which blurs that line even further.'
  topic: technical/GenAI
- impact_reason: Identifies Generative AI (GenAI) as a technology that further complicates
    the existing distinction between deterministic and probabilistic systems, a key
    conceptual challenge in AI adoption.
  relevance_score: 10
  source: llm_enhanced
  text: we've held this audience's hand trying to get them to differentiate between
    deterministic and probabilistic technologies. Now we have GenAI coming down the
    pike, which blurs that line even further.
  topic: AI Technology Trends/Technical
- impact_reason: A strong technical statement asserting that the foundation of modern
    AI/ML (including generative models) is inherently probabilistic, not deterministic.
  relevance_score: 10
  source: llm_enhanced
  text: The outcome of mature learning and our random variables is because the paradigm
    that we're using for everything that we have built is that we're coming from the
    probability space.
  topic: Technical
- impact_reason: 'Crucial warning: AI advancement necessitates parallel advancement
    in cybersecurity, as AI tools can be weaponized against security infrastructure.'
  relevance_score: 10
  source: llm_enhanced
  text: cybersecurity will continue to technically play a huge role in the way on
    how we use AI. In the way on how AI could be used, actually, against cybersecurity
    infrastructure to accessing information.
  topic: Safety/Predictions
- impact_reason: Presents a profound ethical and economic question regarding patient
    data contribution to LLMs/AI development and the right to revenue sharing.
  relevance_score: 10
  source: llm_enhanced
  text: Think about what is going on today with the development of AI or LLM models
    that are large and now that are using maybe information that is protected under
    copyright, right? And they're asking at least that. What does it mean in practice
    for the patient? And my data is helping and contributing to the development of
    the drug. What opportunities do I have to participate in the revenue chart?
  topic: Safety/Ethics/Business
- impact_reason: Highlights a key strategic connection between two seemingly disparate,
    yet data-intensive, industries (AgriTech and HealthTech) using common technological
    approaches (scalable sensing, probabilistic modeling).
  relevance_score: 9
  source: llm_enhanced
  text: Speaking from his academic expertise in clinical trial design, Patricio draws
    compelling connections between the worlds of agriculture and healthcare, where
    scalable sensing technologies and probabilistic modeling are accelerating the
    path to new medicines.
  topic: strategy
- impact_reason: 'Defines the dual role of AI in trials: operational efficiency (low-hanging
    fruit) AND capturing high-value, forward-looking metrics for continuous improvement.'
  relevance_score: 9
  source: llm_enhanced
  text: Where are we deploying AI in these clinical trials, not just to make greater
    efficiencies, make greater automations, do the simple stuff, the low-hanging fruit,
    target patients a little bit better, faster, smarter, take emails a little bit
    easier, but also are drinking in the important metrics that are going to make
    this clinical trial better next time, also clinical trials, clinical trials better
    overall going forward.
  topic: business/strategy
- impact_reason: Highlights the critical dependency on cloud providers for secure,
    compliant, and cost-effective compute infrastructure in highly regulated fields
    like healthcare AI.
  relevance_score: 9
  source: llm_enhanced
  text: The recipient here that comes into picturing everything we do with AI, which
    is a cloud provider. You want to be working on the cloud. You want to be working
    with someone who protects your data, who guarantees hyper-regulation, so that
    the information that you can in and you analyze remains in a protected model.
  topic: business/deployment
- impact_reason: 'A specific example illustrating the computational cost challenge:
    high-complexity R&D models must be optimized or subsidized to survive the transition
    to high-volume clinical deployment.'
  relevance_score: 9
  source: llm_enhanced
  text: I develop a test that develops on highly computational, the models needed
    in order to analyze the data in my area in detail, design, whereas huge computational
    need. Guess what? When I go to the clinical practice, those models are going to
    have to run again and you better have a way to pay for that cost. Otherwise, it
    will be very expensive.
  topic: technical/cost
- impact_reason: 'A clear call to action: technology advancement must be coupled with
    proactive engagement to mature regulatory frameworks, rather than waiting for
    regulation to catch up.'
  relevance_score: 9
  source: llm_enhanced
  text: I think what is still yet to understand is how to make this work leveraging
    the technology so that we can then go to the next step, which is to work with
    the regulatory process so that they can advance and mature according to how the
    technology is advancing.
  topic: strategy/regulation
- impact_reason: 'Emphasizes the dual stakeholder management challenge in AI adoption:
    securing executive buy-in (above) and ensuring end-user/clinical staff understanding
    and trust (below).'
  relevance_score: 9
  source: llm_enhanced
  text: you have to deal with buy-in at two different levels above and below. You
    know, you got to be able to sell folks on this who are in the clinical space and
    don't understand these technologies and might need to understand the advancements
    where it's coming into help people along the journey...
  topic: business/adoption
- impact_reason: Pinpoints the 2010 resurgence of Neural Networks as the practical
    starting point for many current AI applications, marking a significant technological
    inflection point.
  relevance_score: 9
  source: llm_enhanced
  text: For others, it is actually until the rebirth of Neural Networks back in 2010
    when they came back alive, upon after 10 years of being hidden, right?
  topic: AI Technology Trends
- impact_reason: Observes a recent shift (early 2024) where the public/industry is
    beginning to differentiate between different AI capabilities, moving past generalized
    labeling.
  relevance_score: 9
  source: llm_enhanced
  text: I saw that up until I want to say mid-early 2024, and I think it's starting
    to differentiate now, but you know, it really depends on, it depends on the culture,
    it depends on how drastic are the differences in the technology and can people
    see it with their own two eyes...
  topic: AI Technology Trends
- impact_reason: 'Philosophical and technical summary: AI operates on probability,
    which dictates how classifiers, regression, and generative models must be built
    and understood.'
  relevance_score: 9
  source: llm_enhanced
  text: The word of AI builds on chance and organized chance. And so I will say from
    that perspective, everything that you're doing has to apply to the law of probability.
  topic: Technical
- impact_reason: Reiterates the fundamental, non-negotiable responsibility for data
    protection (HIPAA/Security) when deploying AI, framing it as an industry-wide
    baseline.
  relevance_score: 9
  source: llm_enhanced
  text: we have the duty and the responsibility to ensure that patient's information
    is protected. And so no matter what you do with it... this is common across all
    industries, right?
  topic: Safety/Ethics
- impact_reason: Identifies data ownership and the value of proprietary data (especially
    in solving 'big problems') as a major emerging business opportunity.
  relevance_score: 9
  source: llm_enhanced
  text: The new opportunity in the market is that if I am owner of information, everyone
    would like to have a piece of the cake. If I have information that is important,
    right, to solve a big problem, I think we have an opportunity to to technically
    talk about monetization in a different manner.
  topic: Business/Strategy
- impact_reason: A strong prediction that personal, valuable data will evolve into
    a recognized and relevant form of currency in the future economy.
  relevance_score: 9
  source: llm_enhanced
  text: monetization of information is actually another way of currency, which we
    believe in the future will be very relevant.
  topic: Predictions/Business
- impact_reason: Accurately identifies healthcare/life sciences as the most complex
    domain for defining data ownership and intellectual property rights due to privacy
    and societal benefit conflicts.
  relevance_score: 9
  source: llm_enhanced
  text: Nothing complicates questions about what is yours? What is your property more
    than healthcare and life sciences?
  topic: Safety/Ethics
- impact_reason: This encapsulates the core ethical dilemma surrounding the use of
    personal data (often the fuel for medical AI/ML) versus the potential for massive
    societal benefit.
  relevance_score: 9
  source: llm_enhanced
  text: But if that can contribute to the betterment of science and, you know, cures
    that can better humanity overall, do I want to be part of that story?
  topic: Safety/Ethics
- impact_reason: Provides a high-level map of AI application across the drug development
    lifecycle, distinguishing between AI for molecular design (rare diseases) and
    AI for patient engagement/trials.
  relevance_score: 8
  source: llm_enhanced
  text: We really layered out between the entire drug development process where we're
    seeing artificial intelligence of every kind, great through to clinical trials
    and really tried to draw connections between where we're seeing and also draw
    the differences between the kinds of AI that we're seeing in drug development,
    drug targeting, proteins, tailoring those proteins to very, very specific groups
    to make highly advanced drugs for very, very rare diseases and then look at the
    effects downstream...
  topic: AI application scope
- impact_reason: 'A crucial business reality check: AI implementation, especially
    involving new sensing modalities, carries significant upfront and operational
    costs that must be accounted for.'
  relevance_score: 8
  source: llm_enhanced
  text: AI is not for free. And therefore, depending on the sense of modalities that
    we are using, right? Let's say to estimate your particular effect, there is a
    cost associated with it that someone needs to take care of...
  topic: business/cost
- impact_reason: Categorizes a new application of AI in clinical trials by drawing
    a direct parallel to established AI use cases in finance (anomaly detection),
    making it relatable for a broader business audience.
  relevance_score: 8
  source: llm_enhanced
  text: We're now going to bring in a third form of AI, not all that different from
    the anomaly detection that we see in financial services for fraud, KYC, different
    workflows.
  topic: AI application scope
- impact_reason: 'Offers a clear, functional definition of AI''s role in a specific
    domain (clinical/medical data analysis): predict, forecast, prescribe, and analyze.'
  relevance_score: 8
  source: llm_enhanced
  text: I could give you my own definition and the definition that we basically I
    teach in my graduate-level courses where we work on using AI to predict, to forecast,
    and to prescribe and to analyze trials or the medical data or all data.
  topic: Technical/Strategy
- impact_reason: 'A pragmatic view on patient acceptance: efficacy and problem-solving
    often outweigh technical transparency concerns, especially in critical fields
    like healthcare.'
  relevance_score: 8
  source: llm_enhanced
  text: I think at the end of the day, the patient, whatever is being provided that
    he works because at the end of the day, in some cases, some patients might be
    desperate for a solution and they want the problem solved.
  topic: Business/Safety
- impact_reason: Excellent, concrete example illustrating how real-world measurement
    noise necessitates a probabilistic modeling approach, even in complex biological
    data.
  relevance_score: 8
  source: llm_enhanced
  text: I take a swab from your saliva and I take a micro-metagenomics and I get a
    graph that represents all the bacteria and the relative among them. And I take
    it another time. Now I have two graphs that are different and now I have probabilities.
    I can build probabilities on how these two graphs represent from the same person.
  topic: Technical
- impact_reason: Highlights clinical development as a unique environment where diverse
    AI modalities (fraud detection, GenAI, anomaly detection) must coexist and interact.
  relevance_score: 8
  source: llm_enhanced
  text: There are very few places unlike clinical development where you see so many
    different kinds of AI all running through the same place.
  topic: Strategy/AI Technology Trends
- impact_reason: Frames patient data contribution not just as compensation, but as
    a form of investment in the outcome (the cure), appealing to altruism and incentive.
  relevance_score: 8
  source: llm_enhanced
  text: You have this investment in the cure. You have an investment in the cure.
  topic: Strategy/Ethics
- impact_reason: Highlights the critical role of de-identified data in enabling future
    technological (likely AI/ML) solutions in healthcare.
  relevance_score: 8
  source: llm_enhanced
  text: I'll hold another podcast right there about de-identified data, how that builds
    into solutions, both on the medicine side and the technology side for how all
    this goes forward.
  topic: Business/Technical
- impact_reason: Contrasts the 'humanities' side of AI (patient engagement, narrative
    building) with the technical/scientific side, emphasizing the importance of patient
    journey mapping.
  relevance_score: 7
  source: llm_enhanced
  text: '...much similar to what we''re seeing in call centers, much more of the humanities.
    We have to get three people through this journey. That journey is a story. How
    do we connect them to that story? Very different from the kinds of AI that we''re
    seeing in AI.'
  topic: AI application scope
- impact_reason: Points out that AI solutions for scientific discovery do not solve
    the fundamental logistical and human challenges of clinical trial recruitment
    and engagement.
  relevance_score: 7
  source: llm_enhanced
  text: you still are subjective to the ability to find and recruit the people who
    will engage in those trials, as we talked in the previous episode, right? Of course.
    So those things, I don't think we have tackled.
  topic: business/logistics
- impact_reason: Highlights the increasing complexity and layering of different AI
    systems being deployed in workflows (in this case, clinical trials).
  relevance_score: 7
  source: llm_enhanced
  text: But now we're going to encounter yet a third form of AI to make this process
    easier, which is understanding how this happens more and more quickly.
  topic: AI Technology Trends
- impact_reason: Suggests a current practical hierarchy or taxonomy for understanding
    modern AI, separating Deep Learning, broader AI concepts, and foundational Machine
    Learning/Statistics.
  relevance_score: 7
  source: llm_enhanced
  text: I think today we are in distinguishing deep learning techniques, AI, and then
    the rest is much learning and statistics.
  topic: Technical
- impact_reason: Suggests that in practical, cross-industry application, the precise
    technical classification (AI vs. ML vs. Stats) often becomes secondary to results.
  relevance_score: 7
  source: llm_enhanced
  text: I haven't found, neither in the university, neither in the industry, in agriculture,
    people who technically repair too much. Is this really, is this really a statistic,
    or is really, really, really, really, really, right?
  topic: Strategy
- impact_reason: A philosophical appeal to the collective responsibility of data contributors
    and AI developers in advancing human health.
  relevance_score: 7
  source: llm_enhanced
  text: Are we or not companions in enabling health for everyone? Are we or not companions
    in improving humanity as a whole?
  topic: Strategy
- impact_reason: A direct challenge to the audience regarding their personal stance
    on data contribution, relevant for consumer trust in data-driven services.
  relevance_score: 7
  source: llm_enhanced
  text: Maybe that's a question for our listeners to think about going home today.
  topic: Strategy/Ethics
- impact_reason: Provides historical context, reminding the audience that modern AI
    hype often builds on decades-old concepts.
  relevance_score: 6
  source: llm_enhanced
  text: the concept of artificial intelligence goes back to the 1970s and the 1960s.
    Of course, yes, a lot of this stuff has been around for a very, very long time.
  topic: Strategy
- impact_reason: States the foundational privacy concern that must be addressed before
    any large-scale data aggregation for AI training can occur.
  relevance_score: 6
  source: llm_enhanced
  text: the one hand, yes, I don't want everybody knowing my business or how my body
    works necessarily.
  topic: Safety/Ethics
- impact_reason: Host summary of the segment's perceived value.
  relevance_score: 3
  source: llm_enhanced
  text: Truly fascinating stuff.
  topic: General
- impact_reason: Standard closing acknowledgment.
  relevance_score: 2
  source: llm_enhanced
  text: Patricio, really appreciate you being with us.
  topic: General
- impact_reason: Guest response.
  relevance_score: 1
  source: llm_enhanced
  text: Yeah, thank you. I enjoyed the conversation.
  topic: General
- impact_reason: A brief expression of well-wishing.
  relevance_score: 1
  source: llm_enhanced
  text: I hope you're all right.
  topic: General
- impact_reason: Concluding remarks.
  relevance_score: 1
  source: llm_enhanced
  text: It's fine and useful as well, and I wish you all the best.
  topic: General
- impact_reason: Guest closing.
  relevance_score: 1
  source: llm_enhanced
  text: Thank you so much for having me.
  topic: General
source: Unknown Source
summary: '## Podcast Episode Summary: Enhancing Clinical Workflows and Optimizing
  Efficiencies - with Patricio La Rosa at Bayer


  This 29-minute episode of the AI and Business Podcast, featuring Patricio La Rosa,
  Head of N2N Decision Science in Seed Production Innovation at Bayer Crop Science,
  explores the intersection of AI, clinical workflows, and the broader implications
  for drug development and healthcare delivery. The conversation draws parallels between
  agricultural innovation (where La Rosa has expertise) and pharmaceutical R&D, focusing
  on the practical deployment and economic viability of AI-driven sensing technologies.


  ---


  **1. Focus Area**:

  The primary focus is on **enhancing clinical workflows** within drug development
  and clinical trials using AI, specifically addressing the deployment of **scalable
  sensing technologies** and **probabilistic modeling**. Key themes include the transition
  of AI-validated metrics from R&D into scalable clinical practice, the economic constraints
  of advanced computational models, and the necessary evolution of regulatory processes
  to keep pace with technological advancement.


  **2. Key Technical Insights**:

  *   **R&D to Practice Scalability:** A critical challenge is ensuring that sensing
  modalities (like advanced imaging or biomarker detection) developed for R&D—which
  often require high computational power—are industrialized, cost-effective, and scalable
  enough for routine clinical practice post-drug approval.

  *   **Probabilistic Foundation of AI:** From an academic and modeling perspective,
  nearly all modern AI, including deep learning and generative AI, is fundamentally
  built upon the **law of probability** (chance and organized chance), contrasting
  with deterministic phenomena governed by physical laws (like ordinary differential
  equations).

  *   **AI Deployment Layers:** AI is being deployed in clinical trials for process
  automation (low-hanging fruit) but also for ingesting critical metrics that improve
  future trial design—a form of continuous, data-driven optimization.


  **3. Business/Investment Angle**:

  *   **Cost vs. Time Stalemate:** Despite AI integration, the industry average for
  drug development cost (\$1.5B–\$2B) and time (10–15 years) remains stubbornly high,
  suggesting that while AI speeds up marker discovery, regulatory and recruitment
  bottlenecks persist.

  *   **Cloud Economics and Vulnerability:** The high upfront cost of AI infrastructure
  necessitates reliance on cloud providers who can maintain the economy of scale for
  compute power while guaranteeing hyper-regulation and data protection (a key vulnerability
  point).

  *   **Monetization of Patient Data:** A future market opportunity lies in the potential
  **monetization of patient information** that contributes to successful drug development.
  If patient data helps solve major problems, there is a philosophical and economic
  argument for patients to participate in the resulting revenue share, treating data
  as a new form of currency.


  **4. Notable Companies/People**:

  *   **Patricio La Rosa (Bayer Crop Science):** Guest, expert in clinical trial design,
  drawing connections between agriculture and healthcare innovation.

  *   **Matthew Damello (Emerge AI Research):** Host, guiding the discussion on AI
  adoption, ROI, and technological differentiation.

  *   **Cloud Providers:** Mentioned as essential partners for maintaining the necessary
  computational infrastructure and regulatory compliance.


  **5. Future Implications**:

  The industry is moving toward a future where the **regulatory system must mature
  and advance** in parallel with AI technology to avoid becoming the primary bottleneck
  for drug delivery speed. Furthermore, the conversation suggests a significant future
  shift toward **data ownership and incentive structures**, where patients might become
  active financial stakeholders in the cures their data helps create. Cybersecurity
  must advance concurrently with AI capabilities, as smarter analytical tools also
  imply smarter potential threats.


  **6. Target Audience**:

  This episode is highly valuable for **Life Sciences Executives, Clinical Operations
  Leaders, AI Strategists in Pharma/Biotech, and Healthcare Investors** who need to
  understand the practical, economic, and regulatory hurdles facing AI deployment
  in clinical research workflows.'
tags:
- artificial-intelligence
- generative-ai
- investment
title: Enhancing Clinical Workflows and Optimizing Efficiencies - with Patricio La
  Rosa at Bayer
topics:
- keywords:
  - ai
  - machine learning
  - deep learning
  - neural networks
  - llm
  - large language model
  mentions: 73
  prominence: 1.0
  topic: artificial intelligence
- keywords:
  - generative ai
  - genai
  - chatgpt
  - gpt
  - claude
  - text generation
  - image generation
  mentions: 5
  prominence: 0.5
  topic: generative ai
- keywords:
  - investment
  - funding
  - valuation
  - ipo
  - acquisition
  mentions: 3
  prominence: 0.3
  topic: investment
---

<!-- Episode automatically generated from analysis data -->
<!-- Processing completed: 2025-10-04 19:34:59 UTC -->
